Skip to main content

Table 2 Intervention tested and event rates in randomized controlled trials

From: Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

Study

Medications used across groups

Incretin

Control

Duration of treatment (weeks)

Type

Events

Type

Events

Trials reporting heart failure

 Inagaki 2012 [38, 39]

BG or BG + TZD

Exenatide

1/215

Insulin glargine

0/212

26

 NCT00294723 2010 [40, 41]

None

Liraglutide

1/497

Glimepiride

0/248

104

 NCT00318461 2010 [42–44]

Metformin

Liraglutide

1/724

Placebo

0/121

104

Liraglutide

1/724

Glimepiride

0/242

 NCT00360334 2009 [45]

OADs

Exenatide

0/118

Insulin glargine

1/116

26

 NCT00614120 2010 [46]

Merformin

Liraglutide

1/697

Glimepiride

0/231

16

 NCT00701935 2013 [47]

None

Exenatide

0/43

Placebo

1/37

26

 NCT00838903 2014 [48, 49]

Metformin

Albiglutide

2/302

Placebo

0/101

156

Albiglutide

2/302

Glimepiride

1/307

 NCT00838916 2014 [50, 51]

Metformin ± SU

Albiglutide

2/504

Insulin glargine

2/241

156

 NCT00839527 2014 [52]

Metformin + glimepiride

Albiglutide

0/271

Placebo

1/115

164

Albiglutide

0/271

Pioglitazone

4/277

 NCT00849017 2014 [53]

None

Albiglutide

1/200

Placebo

2/101

164

 NCT00849056 2014 [54]

Pioglitazone ± Metformin

Albiglutide

0/150

Placebo

1/151

156

 NCT00855439 2015 [55]

Other diabetes medications

Exenatide

1/22

Glargine

1/24

78

 NCT00960661 2013 [56, 57]

Insulin glargine + metformin

Exenatide

0/315

Insulin lispro

1/312

30

 NCT01064687 2015 [58]

Metformin and pioglitazone

Dulaglutide

1/559

Placebo

0/141

26

Exenatide

0/278

Placebo

0/141

 NCT01075282 2015 [59]

Metformin and glimepiride

Dulaglutide

3/545

Insulin glargine

1/262

78

 NCT01126580 2015 [60, 61]

None

Dulaglutide

1/539

Metformin

0/268

52

 NCT01191268 2014 [62]

Insulin lispro

Dulaglutide

0/588

Insulin glargine

1/296

52

 NCT01512108 2014 [63]

None

Liraglutide

1/240

Additional OAD

0/120

52

 NCT01620489 2014 [64]

OAD and/or insulin

Liraglutide

1/140

Placebo

0/137

26

 Pratley 2013 [65]

SU ± metformin

Taspoglutide

0/494

Pioglitazone

2/257

24

Trials reporting hospitalization for heart failure

 Bentley-Lewis 2015 (ELIXA) [15, 16]

Metformin, SU, glinide, TZD, insulin, metformin and SU, insulin and OADs, or other diabetes medications

Lixisenatide

122/3034

Placebo

127/3034

100

  1. BG biguanide, TZD thiazolidinedione, OADs oral antidiabetic drugs, SU sulfonylurea